Experienced in Hereditary Retinoblastoma

Dr. Mrinal M. Gounder

Oncology
Memorial Solid Tumor Group
160 E 53rd St, 
New York, NY 
Offers Telehealth
Experienced in Hereditary Retinoblastoma
Memorial Solid Tumor Group
160 E 53rd St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mrinal Gounder is an Oncologist in New York, New York. Dr. Gounder and is rated as an Experienced provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Desmoid Tumor, Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Liver Embolization, and Thyroidectomy.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

MEMORIAL SOLID TUMOR GROUP
160 E 53rd St, New York, NY 10022
Other Locations
MEMORIAL SOLID TUMOR GROUP
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: Oraxol
Study Phase: Phase 2
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drug: Tegavivint
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

112 Total Publications

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2025
Similar Doctors
Advanced in Hereditary Retinoblastoma
Dr. Sarah J. Easaw
Oncology | Hematology
Advanced in Hereditary Retinoblastoma
Dr. Sarah J. Easaw
Oncology | Hematology
1255 Route 70, 31 S, 
Lakewood, NJ 
 (49.8 mi)
732-961-0010
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients

Sarah Easaw is an Oncologist and a Hematologist in Lakewood, New Jersey. Dr. Easaw and is rated as a Distinguished provider by MediFind in the treatment of Hereditary Retinoblastoma. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Breast Cancer, and Familial Colorectal Cancer. Dr. Easaw is currently accepting new patients.

Experienced in Hereditary Retinoblastoma
Dr. Raajit K. Rampal
Oncology | Hematology
Experienced in Hereditary Retinoblastoma
Dr. Raajit K. Rampal
Oncology | Hematology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (0.8 mi)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raajit Rampal is an Oncologist and a Hematologist in New York, New York. Dr. Rampal and is rated as an Elite provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Hereditary Retinoblastoma
Dr. Jennifer E. Amengual
Oncology | Hematology | Hematology Oncology
Experienced in Hereditary Retinoblastoma
Dr. Jennifer E. Amengual
Oncology | Hematology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (6.0 mi)
212-305-9876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Amengual is an Oncologist and a Hematologist in New York, New York. Dr. Amengual and is rated as a Distinguished provider by MediFind in the treatment of Hereditary Retinoblastoma. Her top areas of expertise are Non-Hodgkin Lymphoma, T-Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gounder's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 10 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile